A report has concluded that the current regulatory framework in the UK is inadequate for healthcare AI, and makes 44 recommendations to set it right.
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit. Samsung Biologics signed a $262 million...
Officials rubbed shoulders with business leaders in a 19th-floor meeting room to celebrate the launch of Singapore’s newest Overseas Centre.
With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy...
Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach...
Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of...
As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.
Scan to Read